.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Analyze global market entry opportunities
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Johnson and Johnson
Queensland Health
Boehringer Ingelheim
Citi
Harvard Business School
Chubb
Colorcon
Teva
Deloitte
Fuji

Generated: July 26, 2017

DrugPatentWatch Database Preview

Hydromorphone hydrochloride - Generic Drug Details

« Back to Dashboard

What are the generic sources for hydromorphone hydrochloride and what is the scope of hydromorphone hydrochloride patent protection?

Hydromorphone hydrochloride
is the generic ingredient in five branded drugs marketed by Hospira Inc, Nesher Pharms, Aurolife Pharma Llc, Watson Labs, Mallinckrodt Inc, Elite Labs, Akorn, Osmotica, Fresenius Kabi Usa, Lannett, Purdue Pharma Lp, Barr, Actavis Labs Fl Inc, West-ward Pharms Int, Mallinckrodt, Paddock Llc, Rhodes Pharms, and Hospira, and is included in twenty-three NDAs. There are two patents protecting this compound and four Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Hydromorphone hydrochloride has seventeen patent family members in nine countries.

There are fourteen drug master file entries for hydromorphone hydrochloride. Twenty-seven suppliers are listed for this compound.

Summary for Generic Name: hydromorphone hydrochloride

Tradenames:5
Patents:2
Applicants:18
NDAs:23
Drug Master File Entries: see list14
Suppliers / Packagers: see list27
Bulk Api Vendors: see list18
Clinical Trials: see list2,414
Patent Applications: see list6,164
Therapeutic Class:Analgesics
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:hydromorphone hydrochloride at DailyMed

Pharmacology for Ingredient: hydromorphone hydrochloride

Drug ClassOpioid Agonist
Mechanism of ActionFull Opioid Agonists
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Rhodes Pharms
DILAUDID
hydromorphone hydrochloride
TABLET;ORAL019892-003Nov 9, 2007ABRXYesNo► Subscribe► SubscribeYY ► Subscribe
Lannett
HYDROMORPHONE HYDROCHLORIDE
hydromorphone hydrochloride
TABLET;ORAL078439-001Dec 9, 2009ABRXNoNo► Subscribe► Subscribe► Subscribe
Purdue Pharma Lp
PALLADONE
hydromorphone hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL021044-003Sep 24, 2004DISCNNoNo► Subscribe► SubscribeY ► Subscribe
Paddock Llc
HYDROMORPHONE HYDROCHLORIDE
hydromorphone hydrochloride
TABLET, EXTENDED RELEASE;ORAL204278-001Apr 6, 2015ABRXNoNo► Subscribe► Subscribe► Subscribe
Aurolife Pharma Llc
HYDROMORPHONE HYDROCHLORIDE
hydromorphone hydrochloride
TABLET;ORAL205814-001May 13, 2016ABRXNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: hydromorphone hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Purdue Pharma Lp
PALLADONE
hydromorphone hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL021044-003Sep 24, 2004► Subscribe► Subscribe
Purdue Pharma Lp
PALLADONE
hydromorphone hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL021044-003Sep 24, 2004► Subscribe► Subscribe
Mallinckrodt Inc
EXALGO
hydromorphone hydrochloride
TABLET, EXTENDED RELEASE;ORAL021217-003Mar 1, 2010► Subscribe► Subscribe
Purdue Pharma Lp
PALLADONE
hydromorphone hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL021044-001Sep 24, 2004► Subscribe► Subscribe
Purdue Pharma Lp
PALLADONE
hydromorphone hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL021044-002Sep 24, 2004► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: hydromorphone hydrochloride

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,512,117 Hydromorphone and hydrocodone compositions and methods for their synthesis► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: hydromorphone hydrochloride

Country Document Number Estimated Expiration
Canada2854796► Subscribe
Spain2359657► Subscribe
Canada2674424► Subscribe
Japan4886953► Subscribe
Spain2309001► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Moodys
Daiichi Sankyo
US Army
Citi
McKesson
Julphar
Cantor Fitzgerald
Chubb
Colorcon
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot